Side-by-Side Comparison
| Metric | InflaRx | Shaperon |
|---|---|---|
| Founded | ||
| Founded | 2007 older | 2008 |
| Headquarters | ||
| Headquarters | Jena, Germany | Seoul, Korea South |
| Employees | ||
| Employees | 49 | 23 |
| Industry | ||
| Industry | Health Care, Health and Wellness, Pharmaceutical | Biopharma, Biotechnology |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Series C |
| Total Funding | ||
| Total Funding | $250.20M | $26.00B |
| Funding Rounds | ||
| Funding Rounds | 9 | 1 |
| Services | ||
| Services | Development of anti-C5a and C5aR inhibitors, Clinical trials for inflammatory diseases, Research and development of transformative treatments, Commercialization of complement system inhibitors | Not tracked yet |
| Target Customers | ||
| Target Customers | Hospitals treating COVID-19 patients, Healthcare providers, Pharmaceutical industries, Investors in biotechnology | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Biopharmaceutical, Anti-Inflammatory Therapeutics, Anti-C5a Technology, Monoclonal Antibody Development, Chronic Inflammatory Diseases, Complement Activation Inhibitors, Vilobelimab, Oral Small Molecule Inhibitors, C5aR Technology, Acute Inflammation Treatment, Clinical Trials, Drug Discovery, Immunology Research, Complement System Modulation | Immunology, Inflammasome Inhibitors, Clinical Stage Biotech, Novel Modality, Nanobodies, Anti-viral, Anti-cancer, Cytokine Release Syndrome, Alzheimer's Disease, Ulcerative Colitis, NASH, Oncology, Viral Infection Diseases, Inflammatory Disorders, GPCR-regulated P2X7 Inhibition |
| Website | ||
| Website | inflarx.de | shaperon.com |
About InflaRx
InflaRx, founded in 2007, is a Germany-based biopharmaceutical company recognized for pioneering anti-inflammatory therapeutics. The company's slogan, "Controlling Inflammation - developing drugs to treat life threatening and chronic inflammatory diseases," clearly reflects its mission. At the core...
About Shaperon
Shaperon is a clinical stage biotech company with a focus on developing novel inflammasome inhibitors (small molecule). Their unique mechanism of action of GPCR-regulated P2X7 inhibition suppresses a broad spectrum of inflammatory cytokines, including IL-1β, IL-18, IL-6, and TNF-α, by controlling bo...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at InflaRx and Shaperon — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at InflaRx and Shaperon — by email.
Frequently Asked Questions
Compare InflaRx with someone else
Start typing a company name or domain.